Semanteon Capital Management LP Takes Position in DaVita Inc. $DVA

Semanteon Capital Management LP purchased a new position in DaVita Inc. (NYSE:DVA) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 4,223 shares of the company’s stock, valued at approximately $561,000.

Other large investors have also bought and sold shares of the company. Hantz Financial Services Inc. grew its holdings in shares of DaVita by 48.1% during the 2nd quarter. Hantz Financial Services Inc. now owns 231 shares of the company’s stock worth $33,000 after acquiring an additional 75 shares during the period. Canada Pension Plan Investment Board purchased a new stake in DaVita in the second quarter worth $43,000. Employees Retirement System of Texas bought a new position in DaVita in the second quarter worth $49,000. SJS Investment Consulting Inc. lifted its position in DaVita by 3,091.7% during the third quarter. SJS Investment Consulting Inc. now owns 383 shares of the company’s stock valued at $51,000 after buying an additional 371 shares during the period. Finally, MAI Capital Management grew its position in shares of DaVita by 23.4% in the 2nd quarter. MAI Capital Management now owns 438 shares of the company’s stock worth $62,000 after buying an additional 83 shares during the period. 90.12% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

DVA has been the subject of a number of recent research reports. Barclays lifted their price target on shares of DaVita from $143.00 to $158.00 and gave the company an “equal weight” rating in a research report on Tuesday, February 3rd. UBS Group lifted their price objective on DaVita from $186.00 to $190.00 and gave the company a “buy” rating in a research note on Wednesday, February 4th. TD Cowen reiterated a “hold” rating on shares of DaVita in a research note on Tuesday, February 3rd. Truist Financial set a $158.00 target price on DaVita in a report on Thursday, February 5th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of DaVita in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, DaVita has an average rating of “Hold” and an average price target of $155.80.

DaVita Price Performance

NYSE:DVA opened at $150.89 on Friday. DaVita Inc. has a one year low of $101.00 and a one year high of $157.12. The business has a fifty day moving average price of $120.72 and a 200-day moving average price of $125.17. The firm has a market capitalization of $10.08 billion, a price-to-earnings ratio of 15.23, a price-to-earnings-growth ratio of 0.53 and a beta of 0.99.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Monday, February 2nd. The company reported $3.40 EPS for the quarter, topping the consensus estimate of $3.24 by $0.16. The firm had revenue of $3.62 billion for the quarter, compared to the consensus estimate of $3.51 billion. DaVita had a negative return on equity of 413.18% and a net margin of 5.47%.The business’s revenue for the quarter was up 9.9% compared to the same quarter last year. During the same quarter last year, the company earned $2.24 earnings per share. DaVita has set its FY 2026 guidance at 13.600-15.00 EPS. On average, equities research analysts expect that DaVita Inc. will post 10.76 earnings per share for the current fiscal year.

DaVita Profile

DaVita Inc (NYSE: DVA) is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.

Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.